Condition Deep-Dives 10 min read·Updated 22 July 2026 Clinician-reviewed

Atheroembolic Kidney Disease (Cholesterol Embolism)

A UK Consultant Nephrologist on atheroembolic / cholesterol embolic kidney disease — a frequently missed cause of post-procedure AKI in older vasculopathic patients. The diagnosis lives in the constellation: aortic event + sub-acute AKI + livedo + blue toes + transient eosinophilia.

  • Clinically Reviewed
  • NHS & NICE Aligned
  • UK Evidence-Based
  • Last Reviewed 22 July 2026

Professor Mohammed Mahdi Althaf

Consultant Nephrologist & Acute Physician

View Credentials

Professor Mohammed Mahdi Althaf

MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN

Consultant Nephrologist & Acute Physician · GMC 7216325

View profile →

Direct answer

Cholesterol crystal showers from disrupted aortic plaque cause sub-acute AKI 1–4 weeks after cardiac catheterisation, vascular surgery or anticoagulation. Diagnose clinically (livedo, blue toes, eosinophilia) or by biopsy. Treatment is supportive: high-intensity statin, BP and cardiovascular optimisation, avoid further instrumentation. Prognosis is guarded; many need dialysis.

Key recommendation: Always consider 1–4 weeks after aortic procedures.

Quick answer

✓ Best choices

  • Adequate fluids once your team confirms it is safe (often 1.5–2 L/day)
  • Easily digested, nutrient-dense meals during recovery
  • Vegetables, fruit, oats and whole grains as appetite returns
  • Protein in modest portions — typically 0.8–1.0 g/kg/day unless advised otherwise

✓ Foods to limit

  • NSAIDs (ibuprofen, naproxen, diclofenac) — they are nephrotoxic
  • Very salty, processed or ultra-processed foods
  • Alcohol while bloods are still recovering

Key takeaway

Cholesterol crystal showers from disrupted aortic plaque cause sub-acute AKI 1–4 weeks after cardiac catheterisation, vascular surgery or anticoagulation. Diagnose clinically (livedo, blue toes, eosinophilia) or by biopsy. Treatment is supportive: high-intensity statin, BP and cardiovascular optimisation, avoid further instrumentation. Prognosis is guarded; many need dialysis.

Who should be cautious

People on dialysis, post-transplant, pregnant or breastfeeding, or taking prescription medication — confirm with your renal team before changes.

Atheroembolic Kidney Disease (Cholesterol Embolism)

Pathophysiology & triggers

MECHANISM: cholesterol crystals shower from a disrupted atherosclerotic plaque (usually thoracoabdominal aorta) and embolise to small arteries — kidneys, skin, GI tract, retina, CNS. The crystals lodge in arterioles, trigger inflammation and downstream ischaemia.

Classic Triggers

  • Cardiac catheterisation / PCI (commonest)
  • Aortic surgery, EVAR / TEVAR
  • Carotid surgery
  • Thrombolysis (especially streptokinase, tPA)
  • Initiation of warfarin or heparin (haemorrhage into plaque)
  • Spontaneous (in heavily atheromatous aortas)

Risk Factors

  • Age > 60
  • Male
  • Smoker
  • Established atherosclerosis (CAD, PAD, AAA)
  • Diabetes, hypertension, dyslipidaemia
  • Pre-existing CKD

Clinical features & diagnosis

TIME COURSE: 1–4 weeks after trigger (rarely > 8 weeks). Often described as 'stepwise' AKI.

Renal

  • Sub-acute progressive AKI
  • Hypertension (often accelerated)
  • Mild proteinuria, bland sediment

Skin

  • Livedo reticularis (especially flanks, lower limbs, abdomen)
  • Blue/purple toes (peripheral pulses preserved — key distinguishing feature from acute limb ischaemia)
  • Digital gangrene
  • Painful nodules in lower limbs

Eye

  • Hollenhorst plaques (bright orange-yellow cholesterol crystals at retinal arteriolar branch points) on fundoscopy
  • Amaurosis fugax

Gi

  • Abdominal pain, GI bleeding, ischaemic colitis, pancreatitis

Cns

  • Confusion, TIA, focal deficits

Systemic

  • Fever, weight loss, malaise (mimics vasculitis)

Bloods

  • Creatinine rising
  • Eosinophilia (transient, 60–80% of cases)
  • ESR/CRP raised
  • Low complement (especially C3) in 30%
  • Often misdiagnosed as ANCA vasculitis — check ANCA, anti-GBM (negative)

Imaging

  • Renal USS — usually normal
  • Aortic CT/MRA may show extensive plaque

Diagnosis

  • Often clinical (compatible history + features)
  • Tissue diagnosis: SKIN BIOPSY from livedo or nodule — biconvex cholesterol clefts in arterioles (easiest)
  • Kidney biopsy: cholesterol clefts in interlobular arteries (definitive but invasive)
  • Muscle, GI tract biopsy where appropriate

Management & prognosis

Prevention

  • Minimise unnecessary aortic instrumentation in high-risk patients
  • Radial access for coronary angiography preferred where feasible
  • Use lowest contrast volume, minimise catheter exchanges

ACUTE MANAGEMENT (supportive):

  • Stop offending agent if possible (e.g. thrombolytic completed; review anticoagulation indication)
  • High-intensity statin (atorvastatin 80 mg) — observational benefit; stabilises plaque
  • BP control — ACEI/ARB unless contraindicated
  • Manage CKD complications (acidosis, hyperkalaemia, anaemia, MBD)
  • Treat heart failure (diuretics, RAS inhibition)
  • Nutritional support (catabolic illness)
  • Wound care, pain control for skin and toe ischaemia
  • Vascular surgery review for limb-threatening ischaemia

Dialysis

  • Indicated for standard AKI complications (refractory hyperkalaemia, fluid overload, uraemia, severe acidosis)
  • 30–40% will need dialysis at some point
  • Recovery may be slow over weeks–months

Controversial Therapies

  • CORTICOSTEROIDS: no consistent benefit; reserved for selected refractory cases with marked systemic inflammation
  • ICLOPROST / PROSTACYCLIN ANALOGUES: case series for digital ischaemia
  • LDL APHERESIS: anecdotal use in refractory cases

Anticoagulation

  • Weigh original indication vs ongoing crystal showers
  • If anticoagulation precipitated the event, consider stopping when safe
  • DOACs vs warfarin — no clear data showing one is safer in this context

Prognosis

  • Mortality at 1 year: 25–40% (often cardiovascular)
  • 20–40% recover useful kidney function
  • 30–40% require dialysis; some come off, some are long-term
  • Recurrent embolic showers can occur
  • Long-term cardiovascular risk reduction (statin, antiplatelet, BP, glucose, smoking) is essential
Contrast-Induced Nephropathy
Related reading: Contrast-Induced Nephropathy.

Key practical tips

Designed for quick scanning — what to order, what to avoid, sensible portions, common mistakes.

  • Follow the NHS sick-day rules: stop ACE inhibitors, ARBs, NSAIDs and diuretics when dehydrated
  • Re-check eGFR at 3 and 6 months as NICE recommends
  • Tell every clinician you see that you have had AKI

Clinical guidance

TL;DR summary

Cholesterol crystal showers from disrupted aortic plaque cause sub-acute AKI 1–4 weeks after cardiac catheterisation, vascular surgery or anticoagulation. Diagnose clinically (livedo, blue toes, eosinophilia) or by biopsy. Treatment is supportive: high-intensity statin, BP and cardiovascular optimisation, avoid further instrumentation. Prognosis is guarded; many need dialysis.

Key takeaways
  • Always consider 1–4 weeks after aortic procedures.
  • Livedo + blue toes despite palpable pulses = classic.
  • Eosinophilia and low complement support diagnosis.
  • High-intensity statin; supportive care.
  • Steroids are NOT routinely recommended.
Kidney Diet & Nutrition Considerations

After acute kidney injury (AKI) the priority is recovery: rehydration, treating the underlying cause, stopping nephrotoxins and giving the kidneys a calm nutritional environment. Once eGFR is recovering, a balanced Mediterranean-style diet with sensible salt, sensible protein and good hydration supports healing — and reduces the risk of AKI tipping into long-term CKD.

Foods to prioritise

  • Adequate fluids once your team confirms it is safe (often 1.5–2 L/day)
  • Easily digested, nutrient-dense meals during recovery
  • Vegetables, fruit, oats and whole grains as appetite returns
  • Protein in modest portions — typically 0.8–1.0 g/kg/day unless advised otherwise

Foods to limit

  • NSAIDs (ibuprofen, naproxen, diclofenac) — they are nephrotoxic
  • Very salty, processed or ultra-processed foods
  • Alcohol while bloods are still recovering

Potassium, phosphate and protein needs vary between individuals — please confirm personal targets with your renal team or dietitian. Browse the Kidney Diet Hub for more guides in this cluster.

Frequently asked questions

When should I suspect cholesterol embolism?

After any aortic instrumentation (cardiac catheterisation, EVAR, aortic surgery) or anticoagulation/thrombolysis, in a vasculopathic patient who develops sub-acute AKI over days to weeks, livedo reticularis, blue or purple toes despite palpable pulses, transient eosinophilia, low complement, and sometimes Hollenhorst plaques visible on fundoscopy. The classic time course is 1–4 weeks after the trigger, not immediate.

How is it different from contrast nephropathy?

Contrast-induced AKI usually starts within 48–72 hours of contrast and recovers within 1–2 weeks. Cholesterol embolic AKI is sub-acute (1–4 weeks after the procedure), progressive, often stepwise, accompanied by livedo, blue toes, eosinophilia and low complement, and has a much worse renal prognosis. Skin biopsy or kidney biopsy showing cholesterol clefts is diagnostic.

Should anticoagulation be stopped?

If a clear precipitating role for anticoagulation is suspected (e.g. recent thrombolysis or initiation of warfarin/heparin precipitated the embolic shower), stopping if possible is usually advised. However, many patients have strong indications (mechanical valves, recent VTE, AF with high stroke risk) and the risks must be balanced — multidisciplinary discussion is essential. There is no evidence that DOACs are safer or riskier than warfarin in this context.

What treatment helps?

Supportive care is the mainstay: control BP, optimise cardiac status, avoid further arterial instrumentation, manage CKD, treat heart failure. Statins (high-intensity) should be continued or started — observational evidence suggests benefit. Steroids are NOT routinely recommended; trial data are mixed. Avoid warfarin if possible; manage other vascular risk factors aggressively. About 30% of patients require dialysis; renal recovery to a useful baseline occurs in roughly 20–40%.

What should I eat to recover from acute kidney injury?

Most adults recovering from AKI do best on a balanced Mediterranean-style diet with adequate hydration (once your team confirms it's safe), moderate protein (around 0.8–1.0 g/kg/day), lower salt, and avoidance of NSAIDs. Your renal team will give you personalised fluid and protein targets based on your recovery.

Nutritional challenges in kidney disease

Many people living with kidney disease have to limit foods because of potassium, phosphate, diabetes, dialysis, appetite changes or simply the time it takes to cook from scratch every day. That can make it harder to keep daily nutrition balanced — particularly for vitamins and minerals that food alone may not fully cover.

Kidney Vitality is a UK-formulated daily nutritional support product designed by Consultant Nephrologist Professor Mohammed Mahdi Althaf with renal nutrition in mind from the start. It keeps doses moderate, leaves out added potassium, phosphate and magnesium, and avoids megadose vitamin A — sitting alongside a kidney-friendly diet, not replacing it.

Why Kidney Vitality fits this need

Built around UK guidance

Aligned with British Cardiovascular Intervention Society contrast and access recommendations, UK Kidney Association AKI guidance, and NICE lipid modification guidance.

Designed by a UK Consultant Nephrologist

Formulated and reviewed by Professor Mohammed Mahdi Althaf (GMC 7216325).

Distinguishes from contrast & vasculitis

Clear diagnostic framework to separate cholesterol embolism from contrast-induced AKI, ANCA vasculitis and acute limb ischaemia.

Designed by a UK Consultant Nephrologist

Ready to support your kidney health?

If you have been researching kidney health, supplements, CKD nutrition or kidney-friendly living, Kidney Vitality was developed specifically around those principles by Professor Mohammed Mahdi Althaf (GMC 7216325). Nephrologist Developed Daily Multivitamin.

  • No Added Potassium
  • No Added Magnesium
  • No Added Phosphorus
  • No Added Iron
  • One capsule daily
  • UK GMP — BRCGS, NSF GMP, Halal
Subscribe & Save — £20.39/monthCheck your current multivitamin

✓ Free UK tracked delivery  ·  ✓ Delivered every 30 days  ·  ✓ Pause or cancel anytime  ·  ✓ Never run out

ComparisonKidney VitalityTypical high-street multivitamin
Added potassiumNoneOften included
Added phosphateNoneOften included (E338–E452)
Vitamin A (retinol)No megadoseOften high-dose retinol
Kidney-focused formulationYesNo — general population
Consultant Nephrologist involvementYes (GMC 7216325)No
UK GMP manufacturedYes (BRCGS, NSF GMP)Varies

Food supplement. Not a medicine and not a treatment for kidney disease. Speak with your GP, pharmacist or renal team before starting any new supplement, especially in advanced CKD, on dialysis, post-transplant, pregnant or breastfeeding.

Clinical reviewer

Professor Mohammed Mahdi Althaf

Consultant Nephrologist

Acute Physician

GMC 7216325

View Full Biography

Professor Mohammed Mahdi Althaf is a UK Consultant Nephrologist and Acute Physician with a special interest in chronic kidney disease, AKI prevention and renal nutrition. He combines hospital practice with patient education and clinical guidance review.

View professional profile →
View Credentials
  • MD
  • MSc
  • PgDip (Clin Ed)
  • FRCP
  • FHEA
  • FASN

About this article

Written for UK patients and based on:

  • NICE guidance
  • NHS resources
  • British Dietetic Association guidance
  • Kidney Care UK resources
View methodology

Each article is researched against current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO and KDOQI international guidelines, and the British Dietetic Association Renal Nutrition Group. Drafts are written by the Kidney Vitality editorial team and reviewed by a UK Consultant Nephrologist before publication. Content is reviewed on a rolling basis and updated when guidance changes.

Editorial standards

  • Clinically reviewed
  • NHS-aligned
  • NICE-aligned
  • Evidence-based
  • Reviewed before publication
View full editorial process

Every article is researched and written by the Kidney Vitality editorial team using current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO/KDOQI international guidelines, and British Dietetic Association renal nutrition guidance. Drafts are reviewed for clinical accuracy by Professor Mohammed Mahdi Althaf, MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN (Consultant Nephrologist & Acute Physician, GMC 7216325) before publication. Content is updated when UK guidance changes.

References (4)View Sources
  1. NICE NG203: Chronic kidney disease — assessment and management
  2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
  3. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update
  4. British Dietetic Association — Renal Nutrition Group

Medical disclaimer

This content is educational only and does not replace personalised medical advice.

Read full disclaimer

This page is general information, not personal medical advice. If you have chronic kidney disease, are on dialysis, have had a kidney transplant, are pregnant or breastfeeding, or take prescription medication, please confirm any supplement with your GP, pharmacist or renal team before starting.

← Back to all guides